Dare Bioscience Inc (DARE)

$1.74 -0.16 (-8.42%)
Market Cap 25.33M
Revenue (ttm) 1.03M
Net Income (ttm) -13.40M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -1,300.97%
Debt to Equity Ratio 0.00
Volume 94,400
Avg Vol 89,494
Day's Range N/A - N/A
Shares Out 14.56M
Stochastic %K 71%
Beta 0.90
Analysts Strong Sell
Price Target $10.25

Company Profile

Daré Bioscience, Inc. develops therapies in the areas of contraception, pelvic pain, fertility, infectious disease, menopause, and sexual and vaginal health in the United States. The company offers XACIATO, a lincosamide antibacterial gel for the treatment of bacterial vaginosis. It also develops Ovaprene, a hormone-free monthly intravaginal contraceptive; Sildenafil Cream, a cream formulation of sildenafil for topical administration to the female genitalia for the treatment of female sexual aro...

Industry: Biotechnology
Sector: Healthcare
Phone: 858 926 7655
Address:
3655 Nobel Drive, Suite 260, San Diego, United States
BuyAndHoldStocks
BuyAndHoldStocks Apr. 1 at 9:47 PM
$DARE This week they have added significant changes to the current offering due to delisting risk. Volume is waiting to be dumped on unsuspecting buyers. Read the 10-K
0 · Reply
BuyAndHoldStocks
BuyAndHoldStocks Apr. 1 at 9:26 PM
$DARE Volume on Close drops 📉⚠️
0 · Reply
BuyAndHoldStocks
BuyAndHoldStocks Apr. 1 at 7:54 PM
$DARE no volume - prime to drop
1 · Reply
Bocholter
Bocholter Apr. 1 at 7:39 PM
$DARE up to $2🤑🤑🤑
0 · Reply
Bocholter
Bocholter Apr. 1 at 7:35 PM
$DARE oooooo let’s party started 🙏🥳🥳🥳
0 · Reply
BuyAndHoldStocks
BuyAndHoldStocks Apr. 1 at 7:27 PM
$DARE Description: Reflects information that constitutes a substantive change from or addition to the information set forth in the last offering circular. 🔜 📉
0 · Reply
Bocholter
Bocholter Apr. 1 at 6:16 PM
$DARE next earnings coming soon 😎🥳🥳
1 · Reply
Bocholter
Bocholter Apr. 1 at 6:15 PM
$DARE extremely bullish 🤑🤑🤑
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Apr. 1 at 5:18 PM
$DARE RSI: 73.59, MACD: 0.0249 Vol: 0.16, MA20: 1.51, MA50: 1.65 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
Green_Party
Green_Party Apr. 1 at 4:34 PM
$DARE's dilution situation is kinda nuanced. Dare needs more money and will have to dilute eventually. But it did huge dilution last July and due to the "baby-shelf" rule is limited from doing more for a full year. That's why it's done that wonky model that's not gotten much traction (only about 120k shares sold). Most of the recent downturn probably hasn't been due to dilution. That said, they'll probably do the Real Dilution in July or August. But there are a few short-term catalysts before then (Dare to Play & Dare to Restore commercialization and potential early numbers at earnings call). So an odd window where there will probably be lots of volatility.
0 · Reply
Latest News on DARE
Daré Bioscience Reports Full Year 2025 Financial Results and Provides Business Update

Mar 26, 2026, 4:01 PM EDT - 9 days ago

Daré Bioscience Reports Full Year 2025 Financial Results and Provides Business Update

On National Viagra Day, Women Finally Claim Their Turn:

Mar 23, 2026, 8:00 AM EDT - 13 days ago

On National Viagra Day, Women Finally Claim Their Turn:

Daré Bioscience Receives NIH Funding Award Notice to Advance DARE-PTB1, its Novel Intravaginal Ring for Prevention of Preterm Birth

Mar 16, 2026, 8:00 AM EDT - 20 days ago

Daré Bioscience Receives NIH Funding Award Notice to Advance DARE-PTB1, its Novel Intravaginal Ring for Prevention of Preterm Birth

Daré Bioscience Participates in Virtual Investor “What This Means” Segment

Mar 12, 2026, 8:00 AM EDT - 24 days ago

Daré Bioscience Participates in Virtual Investor “What This Means” Segment

Daré Bioscience Announces FDA Clearance of IND for Phase 2 Clinical Study of DARE-HPV, a Potential Treatment for Persistent High-Risk HPV Infection, the Most Common Cause of Cervical Cancer

Feb 23, 2026, 8:00 AM EST - 5 weeks ago

Daré Bioscience Announces FDA Clearance of IND for Phase 2 Clinical Study of DARE-HPV, a Potential Treatment for Persistent High-Risk HPV Infection, the Most Common Cause of Cervical Cancer

DARE to PLAY™ Sildenafil Cream Now Available for Pre-Order by Prescription: First Evidence-Based Topical Arousal Cream for Women Begins Commercial Rollout in Select States via 503B Outsourcing Facility

Dec 10, 2025, 8:00 AM EST - 4 months ago

DARE to PLAY™ Sildenafil Cream Now Available for Pre-Order by Prescription: First Evidence-Based Topical Arousal Cream for Women Begins Commercial Rollout in Select States via 503B Outsourcing Facility

Daré Bioscience Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Nov 13, 2025, 4:01 PM EST - 5 months ago

Daré Bioscience Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Daré Bioscience to Host Third Quarter 2025 Financial Results and Company Update Conference Call and Webcast on November 13, 2025

Nov 6, 2025, 8:00 AM EST - 5 months ago

Daré Bioscience to Host Third Quarter 2025 Financial Results and Company Update Conference Call and Webcast on November 13, 2025

Daré Bioscience to Receive up to $499,000 to Support Preeclampsia Research

Sep 24, 2025, 8:00 AM EDT - 6 months ago

Daré Bioscience to Receive up to $499,000 to Support Preeclampsia Research

Daré Bioscience Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Aug 14, 2025, 4:01 PM EDT - 8 months ago

Daré Bioscience Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Daré Bioscience to Host Second Quarter 2025 Financial Results and Company Update Conference Call and Webcast on August 14, 2025

Aug 7, 2025, 8:00 AM EDT - 8 months ago

Daré Bioscience to Host Second Quarter 2025 Financial Results and Company Update Conference Call and Webcast on August 14, 2025

Daré Bioscience and Rosy Wellness Launch First Phase of Patient-Focused Campaign to Support DARE to PLAY™ Sildenafil Cream

Jul 29, 2025, 8:00 AM EDT - 8 months ago

Daré Bioscience and Rosy Wellness Launch First Phase of Patient-Focused Campaign to Support DARE to PLAY™ Sildenafil Cream

UPDATE - Daré Bioscience to Host August 6 Webinar: The DARE to PLAY™ Difference - The Sildenafil Cream That Raises the Bar

Jul 21, 2025, 1:47 PM EDT - 9 months ago

UPDATE - Daré Bioscience to Host August 6 Webinar: The DARE to PLAY™ Difference - The Sildenafil Cream That Raises the Bar

Crude Oil Moves Lower; Daré Bioscience Shares Jump

Jul 14, 2025, 1:09 PM EDT - 9 months ago

Crude Oil Moves Lower; Daré Bioscience Shares Jump

Positive Interim Phase 3 Results Highlight Potential of Ovaprene®, Novel Hormone-Free Contraceptive

Jul 14, 2025, 8:00 AM EDT - 9 months ago

Positive Interim Phase 3 Results Highlight Potential of Ovaprene®, Novel Hormone-Free Contraceptive

Daré Bioscience Receives $6 Million Non-Dilutive Grant Installment; $37.8M to Date of up to $49M Commitment Supporting Smart Drug Delivery Device for Contraception; Platform has Broader Application Potential in Obesity and Metabolic Disorders

Jul 11, 2025, 8:00 AM EDT - 9 months ago

Daré Bioscience Receives $6 Million Non-Dilutive Grant Installment; $37.8M to Date of up to $49M Commitment Supporting Smart Drug Delivery Device for Contraception; Platform has Broader Application Potential in Obesity and Metabolic Disorders

Daré Bioscience Announces Adjournment of Annual Meeting of Stockholders

Jun 12, 2025, 5:00 PM EDT - 10 months ago

Daré Bioscience Announces Adjournment of Annual Meeting of Stockholders

Daré Bioscience Reports First Quarter 2025 Financial Results and Provides Company Update

May 13, 2025, 4:01 PM EDT - 11 months ago

Daré Bioscience Reports First Quarter 2025 Financial Results and Provides Company Update

Daré Bioscience Reports Full Year 2024 Financial Results and Provides Company Update

Mar 31, 2025, 4:01 PM EDT - 1 year ago

Daré Bioscience Reports Full Year 2024 Financial Results and Provides Company Update

Daré Bioscience to Host Full Year 2024 Financial Results and Company Update Conference Call and Webcast on March 31, 2025

Mar 24, 2025, 8:00 AM EDT - 1 year ago

Daré Bioscience to Host Full Year 2024 Financial Results and Company Update Conference Call and Webcast on March 31, 2025

Daré Bioscience Announces Funding Award Notice from the National Institutes of Health (NIH) National Institute of Allergy and Infectious Diseases (NIAID) to Support DARE-HPV Development

Feb 6, 2025, 8:00 AM EST - 1 year ago

Daré Bioscience Announces Funding Award Notice from the National Institutes of Health (NIH) National Institute of Allergy and Infectious Diseases (NIAID) to Support DARE-HPV Development

Daré Bioscience to Participate in the Women's Health Series at the 43rd Annual J.P. Morgan Healthcare Conference

Jan 9, 2025, 8:00 AM EST - 1 year ago

Daré Bioscience to Participate in the Women's Health Series at the 43rd Annual J.P. Morgan Healthcare Conference

Daré Bioscience Reports Third Quarter 2024 Financial Results and Provides Company Update

Nov 14, 2024, 4:01 PM EST - 1 year ago

Daré Bioscience Reports Third Quarter 2024 Financial Results and Provides Company Update

Daré Bioscience to Host Third Quarter 2024 Financial Results and Company Update Conference Call and Webcast on November 14, 2024

Nov 7, 2024, 8:00 AM EST - 1 year ago

Daré Bioscience to Host Third Quarter 2024 Financial Results and Company Update Conference Call and Webcast on November 14, 2024

Daré Bioscience Selected to Receive $10 Million Award from ARPA-H's Sprint for Women's Health

Oct 23, 2024, 12:30 PM EDT - 1 year ago

Daré Bioscience Selected to Receive $10 Million Award from ARPA-H's Sprint for Women's Health

Daré Bioscience Announces Common Stock Purchase Agreement for up to $15 Million with Lincoln Park Capital Fund, LLC

Oct 21, 2024, 8:05 AM EDT - 1 year ago

Daré Bioscience Announces Common Stock Purchase Agreement for up to $15 Million with Lincoln Park Capital Fund, LLC

Daré Bioscience Reports Second Quarter 2024 Financial Results and Provides Company Update

Aug 12, 2024, 4:01 PM EDT - 1 year ago

Daré Bioscience Reports Second Quarter 2024 Financial Results and Provides Company Update

Daré Bioscience Regains Compliance with Nasdaq Minimum Bid Price Rule

Jul 19, 2024, 8:00 AM EDT - 1 year ago

Daré Bioscience Regains Compliance with Nasdaq Minimum Bid Price Rule

Biotech Executive Lisa Walters-Hoffert Joins Kiora Pharmaceuticals' Board of Directors

Jul 1, 2024, 6:54 AM EDT - 1 year ago

Biotech Executive Lisa Walters-Hoffert Joins Kiora Pharmaceuticals' Board of Directors

KPRX

Daré Bioscience Announces Reverse Stock Split

Jun 27, 2024, 8:00 AM EDT - 1 year ago

Daré Bioscience Announces Reverse Stock Split

Daré Bioscience Reports First Quarter 2024 Financial Results and Provides Company Update

May 14, 2024, 8:00 AM EDT - 2 years ago

Daré Bioscience Reports First Quarter 2024 Financial Results and Provides Company Update

Daré Bioscience Selected as a Member of ARPA-H Investor Catalyst Hub Spoke Network

May 2, 2024, 8:00 AM EDT - 2 years ago

Daré Bioscience Selected as a Member of ARPA-H Investor Catalyst Hub Spoke Network

Daré Bioscience Secures $22 Million in Non-Dilutive Strategic Royalty Financing to Advance Phase 3 First-in-Category Women's Health Product Candidates through Key Catalysts

Apr 30, 2024, 7:30 AM EDT - 2 years ago

Daré Bioscience Secures $22 Million in Non-Dilutive Strategic Royalty Financing to Advance Phase 3 First-in-Category Women's Health Product Candidates through Key Catalysts

Daré Bioscience Announces Grant Funding Installment to Support Further Development of Novel Contraceptive Technology DARE-LARC1

Apr 23, 2024, 8:00 AM EDT - 2 years ago

Daré Bioscience Announces Grant Funding Installment to Support Further Development of Novel Contraceptive Technology DARE-LARC1

Daré Bioscience Announces Publication in Contraception of Positive Efficacy and Safety Findings from a Pre-Pivotal Postcoital Test Study of Ovaprene®: an Investigational Hormone-Free Monthly Intravaginal Contraceptive

Apr 11, 2024, 8:00 AM EDT - 2 years ago

Daré Bioscience Announces Publication in Contraception of Positive Efficacy and Safety Findings from a Pre-Pivotal Postcoital Test Study of Ovaprene®: an Investigational Hormone-Free Monthly Intravaginal Contraceptive

Daré Bioscience Reports Full Year 2023 Financial Results and Provides Company Update

Mar 28, 2024, 8:00 AM EDT - 2 years ago

Daré Bioscience Reports Full Year 2023 Financial Results and Provides Company Update

Daré Bioscience to Host Full Year 2023 Financial Results and Company Update Conference Call and Webcast on March 28, 2024

Mar 21, 2024, 8:00 AM EDT - 2 years ago

Daré Bioscience to Host Full Year 2023 Financial Results and Company Update Conference Call and Webcast on March 28, 2024

This overlooked corner of women's health could be a $350 billion market opportunity

Mar 15, 2024, 2:33 PM EDT - 2 years ago

This overlooked corner of women's health could be a $350 billion market opportunity

PFE PGNY VTGN BTMD

Daré Bioscience Announces Positive End-of-Phase 2 Meeting with FDA on Development of Sildenafil Cream, 3.6% in Female Sexual Arousal Disorder and Provides Company Focus Areas for 2024

Jan 31, 2024, 8:00 AM EST - 2 years ago

Daré Bioscience Announces Positive End-of-Phase 2 Meeting with FDA on Development of Sildenafil Cream, 3.6% in Female Sexual Arousal Disorder and Provides Company Focus Areas for 2024

Daré Bioscience Announces Executive Team and Board of Directors Changes

Jan 26, 2024, 4:30 PM EST - 2 years ago

Daré Bioscience Announces Executive Team and Board of Directors Changes

Daré Bioscience Announces Grant to Support Biotherapeutic Product Development

Jan 17, 2024, 8:00 AM EST - 2 years ago

Daré Bioscience Announces Grant to Support Biotherapeutic Product Development

Daré Bioscience's DARE-LARC1 Platform Technology Achieves Proof-of-Concept Device that has Transformative Potential for Women's Health as well as in Treating a Broad Range of Diseases

Jan 4, 2024, 8:00 AM EST - 2 years ago

Daré Bioscience's DARE-LARC1 Platform Technology Achieves Proof-of-Concept Device that has Transformative Potential for Women's Health as well as in Treating a Broad Range of Diseases

Daré Bioscience Secures $12 million in Royalty-backed Investment Structure

Dec 26, 2023, 8:00 AM EST - 2 years ago

Daré Bioscience Secures $12 million in Royalty-backed Investment Structure

Daré Bioscience Announces Positive Topline Pharmacokinetic and Exploratory Efficacy Results from the DARE-PDM1 Phase 1 Clinical Study

Dec 20, 2023, 8:00 AM EST - 2 years ago

Daré Bioscience Announces Positive Topline Pharmacokinetic and Exploratory Efficacy Results from the DARE-PDM1 Phase 1 Clinical Study

Daré Bioscience Announces Funding Award Notice from the National Institutes of Health (NIH) Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) to Support DARE-PTB1 Phase 1 Human Clinical Study

Dec 13, 2023, 8:00 AM EST - 2 years ago

Daré Bioscience Announces Funding Award Notice from the National Institutes of Health (NIH) Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) to Support DARE-PTB1 Phase 1 Human Clinical Study

Daré Bioscience Reports Third Quarter 2023 Financial Results and Provides Company Update

Nov 9, 2023, 8:00 AM EST - 2 years ago

Daré Bioscience Reports Third Quarter 2023 Financial Results and Provides Company Update

Daré Bioscience to Participate in Three November Conferences

Nov 6, 2023, 8:00 AM EST - 2 years ago

Daré Bioscience to Participate in Three November Conferences

Daré Bioscience Announces Additional Positive Data from Phase 2b RESPOND Study of Sildenafil Cream, 3.6% in Women and Proposed Endpoints and Patient Population for Phase 3 Program

Nov 1, 2023, 8:00 AM EDT - 2 years ago

Daré Bioscience Announces Additional Positive Data from Phase 2b RESPOND Study of Sildenafil Cream, 3.6% in Women and Proposed Endpoints and Patient Population for Phase 3 Program

Daré Bioscience Announces $7.0 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules

Aug 30, 2023, 8:00 AM EDT - 2 years ago

Daré Bioscience Announces $7.0 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules

Daré Bioscience Reports Second Quarter 2023 Financial Results and Provides a Company Update

Aug 10, 2023, 8:00 AM EDT - 2 years ago

Daré Bioscience Reports Second Quarter 2023 Financial Results and Provides a Company Update

BuyAndHoldStocks
BuyAndHoldStocks Apr. 1 at 9:47 PM
$DARE This week they have added significant changes to the current offering due to delisting risk. Volume is waiting to be dumped on unsuspecting buyers. Read the 10-K
0 · Reply
BuyAndHoldStocks
BuyAndHoldStocks Apr. 1 at 9:26 PM
$DARE Volume on Close drops 📉⚠️
0 · Reply
BuyAndHoldStocks
BuyAndHoldStocks Apr. 1 at 7:54 PM
$DARE no volume - prime to drop
1 · Reply
Bocholter
Bocholter Apr. 1 at 7:39 PM
$DARE up to $2🤑🤑🤑
0 · Reply
Bocholter
Bocholter Apr. 1 at 7:35 PM
$DARE oooooo let’s party started 🙏🥳🥳🥳
0 · Reply
BuyAndHoldStocks
BuyAndHoldStocks Apr. 1 at 7:27 PM
$DARE Description: Reflects information that constitutes a substantive change from or addition to the information set forth in the last offering circular. 🔜 📉
0 · Reply
Bocholter
Bocholter Apr. 1 at 6:16 PM
$DARE next earnings coming soon 😎🥳🥳
1 · Reply
Bocholter
Bocholter Apr. 1 at 6:15 PM
$DARE extremely bullish 🤑🤑🤑
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Apr. 1 at 5:18 PM
$DARE RSI: 73.59, MACD: 0.0249 Vol: 0.16, MA20: 1.51, MA50: 1.65 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
Green_Party
Green_Party Apr. 1 at 4:34 PM
$DARE's dilution situation is kinda nuanced. Dare needs more money and will have to dilute eventually. But it did huge dilution last July and due to the "baby-shelf" rule is limited from doing more for a full year. That's why it's done that wonky model that's not gotten much traction (only about 120k shares sold). Most of the recent downturn probably hasn't been due to dilution. That said, they'll probably do the Real Dilution in July or August. But there are a few short-term catalysts before then (Dare to Play & Dare to Restore commercialization and potential early numbers at earnings call). So an odd window where there will probably be lots of volatility.
0 · Reply
SnowBison
SnowBison Apr. 1 at 2:58 PM
$DARE hope to see a profit and revenue steady increase in next earning report. Glad I have small position 3k shares @ $1.56
0 · Reply
DonnaTroy
DonnaTroy Mar. 31 at 1:30 AM
$DARE
0 · Reply
DonnaTroy
DonnaTroy Mar. 31 at 1:07 AM
$DARE 2$ next up
0 · Reply
peepthestamp
peepthestamp Mar. 30 at 11:03 PM
$DARE -Buy Lows
0 · Reply
BuyAndHoldStocks
BuyAndHoldStocks Mar. 30 at 8:53 PM
$DARE I'll buy some after they dilute it further. They need to raise money before the summer. They can't even tell you how many prescriptions they've received so far, so the number is probably negligible at this point. Update on Ovaprene will come first H2 according to the 10-k.
0 · Reply
BuyAndHoldStocks
BuyAndHoldStocks Mar. 30 at 8:39 PM
$DARE The fact that the CEO is optimistic in CC indicates a desperate situation where they do not have many opportunities to raise money in a way that is good for shareholders. Imo. Read 10-k
0 · Reply
Teddy313
Teddy313 Mar. 30 at 8:35 PM
$DARE Doesn't mean a thing BIOS have been raising $$$$ from the beginning of time, the thing is they have a fantastic pipeline.IMO. 2026 is the year to make investors happy that's good enough for me, came from a good source.
0 · Reply
BuyAndHoldStocks
BuyAndHoldStocks Mar. 30 at 8:34 PM
$DARE imo
0 · Reply
BuyAndHoldStocks
BuyAndHoldStocks Mar. 30 at 8:07 PM
$DARE https://ir.darebioscience.com/static-files/e8ac1aab-207f-409a-9320-536df91849cb
0 · Reply
4gme8
4gme8 Mar. 30 at 7:53 PM
$DARE DILUTION is coming...!
0 · Reply
Teddy313
Teddy313 Mar. 30 at 6:26 PM
$DARE Remember the words of Sabrina over and over again, "it took us 10 years to get here now 2026 is the time for investors to be happy". 50 years in the market I never heard this before from anyone, something is up and I can't wait because I'm loaded....SM I'm happy already because the stock just woke up...
0 · Reply
Placebo73
Placebo73 Mar. 30 at 5:27 PM
$DARE but why this movement, if cash is so restricted, and Nasdaq requirements are in jeopardy.......pump and dump?
0 · Reply